Breast Cancer is the most commonly diagnosed malignancy in women.
You may not treat cancer in your practice, but you do have patients who are at risk due to personal and family history, patients who may be undergoing or recovering from treatments, patients who are survivors worried about recurrence and patients living with cancer as a chronic illness. And you may also have patients who are family members concerned about their loved ones.
There is no HEALTH MODEL in conventional oncology care, yet health and wellbeing, peace of mind and sense of agency are in the center of the hearts and minds of cancer patients, cancer survivors and their families.
There will be 19 million cancer survivors in the US alone by 2024. Who is supporting their health? Who is trained to help them recover and keep them well?? …not the oncologist.
How can you help these patients?
A breast cancer survivor who successfully completed her treatments 8 years ago comes into your office as a new patient complaining of persistent peripheral neuropathy and ongoing cognitive changes since her treatment. How can you resolve these long-term adverse effects?
An ovarian cancer patient currently undergoing aggressive treatment every 21 days comes into your office complaining of severe diarrhea, neuropathy and sleep disruption. What can you do to help her get through her treatments with less adverse effects, maintain her weight and nutritional status?
A colorectal cancer survivor who completed his treatment 3 months ago is continuing to have 10-15 bowel movements daily and is profoundly fatigued. What will you do to restore normal bowel function?
A prostate cancer patient on endocrine blockade therapy is suffering from hot flashes. Should you also be concerned about loss of bone mass and sleep cycle disruption?
An endometrial cancer survivor is suffering from dermatitis and colitis, adverse effects of her dramatically successful immunotherapy treatment and now has chronic autoimmune inflammation. How will you manage this?
A head and neck cancer patient who has trouble swallowing is losing weight and muscle mass.
How can you provide a plan for repair from oral mucositis, restoration of the oral mircrobiome and repletion of calories and nutrients?
These patients are searching for clinicians that can guide and support them through every phase of their cancer journey. Just as in helping your patients navigate other chronic illnesses, patients look to you for a plan, for monitoring and guidance so that they can maintain and regain their health during and after their treatments.
When a patient has a collaborative team providing integrative care everyone wins, the patients, families and care providers. Patients who have a clear plan and support have the opportunity for better outcomes, better prognosis, greater peace of mind, a sense of control and agency and an improved quality of life.
Let the oncologist be the cancer expert. You can be the health expert on their team.
Standard of care in oncology must change such that care includes not only a team of disease experts (usually medical oncologist, surgeon, radiologist) but ALSO a team of health experts.
Towards this end I founded the American Institute of Integrative Oncology Research and Education and have created an online self-paced training program for front line clinicians who want to expand their skills and their practice and fill the huge need in our communities and serve these patients. If you did not specialize in oncology, you probably had one course on this topic but you need to fill the gap in your training to feel confident in doing so.
The Foundations of Integrative Oncology Training is not for clinicians who want to practice oncology. It is front-line clinicians who want to feel confident, knowledgeable and well trained in supporting the health side of the cancer equation. This self- paced online training is for clinicians who want to increase their impact, expand and grow their practice and represents 35 years of clinical practice and experience.
The first step is learning how to take a comprehensive and complete history of patients whose lives have been touched by cancer.
You can receive a complimentary copy of the
and learn more about the Foundations of Integrative Oncology training here
A diet high in polyunsaturated fatty acids, especially omega 3s, have been shown to be negatively associated with cancer development
Dietary fatty acids have been recognized as influential factors in the activation of carcinogenic events or disease progression and have been associated with a direct connection to breast cancer prevention.
PUFAs differentially inhibit mammary tumor development by inflicting modifications to the morphology of cell membranes, and influencing signaling pathways, gene expression and apoptosis.
The human body is unable to synthesize long-chain polyunsaturated fatty acids (PUFAs) Omega 3 DHA, docosahexaenoic, and EPA, Eicosapentaenoic acid and Omega 6 Arachidonic Acid at a reasonable rate and therefore, supplementation is required through dietary sources or nutritional supplements. The recommended daily nutritional dose is 2,000 mg EPA+DHA, while therapeutic dosing is 4,000-6,000 milligrams of EPA+DHA per day.
Omega Three Fatty Acids and the Tumor Microenvironment
How to Measure Omega 3 Fatty Acid Status
Serum or plasma omega-3 fatty acid ratios are readily accessible and available from most medical clinical labs. However, I recommend the OmegaQuant Omega-3 Index for measuring omega-3 status(omegaquant.com).
This cost-effective test was developed by a world expert in omega-3s and human health: Bill Harris, PhD, founder of OmegaQuant. Using a finger-stick at-home collection method, the test assesses the fatty-acid composition of the red blood cell membrane—not plasma.
OmegaQuant’s Omega-3 Index is defined as the amount of EPA plus DHA in red blood cell membranes, expressed as the percent of total red blood cell membrane fatty acids. Omega-3 levels of 8-12 percent are associated with better overall health.
For an in-depth discussion of the OmegaQuant Omega-3 Index, listen to the Dr. Bill Harris interview on the The Peter Attia Drive Podcast #83 (December 9, 2019). You can find the podcast at peterattiamd.com/billharris/.
Fish Oil Sourced
DFH Omegavail TG 1000 capsules 2 caps 2x/day = 4 caps = 4000mg
Metagenics EPA DHA 1000 capsules
- 2 caps 2x/day = 4 caps = 4000mg
DFH Omegavail Smoothie (emulsified-flavored liquid)
- Lemon Drop, Key Lime and Citrus Sorbet Flavors
- 3 Tablespoons daily = 4410 mg EPA DHA
Pharmax Ultra EPA DHA Liquid/Orange
- 1 1/2 teaspoons = 4522 mg 2 teaspoons = 5840 mg EPA DHA
It is challenging to achieve therapeutic dosing with Plant Sourced supplements of Omega 3 Fatty Acids
Algae Oil Sourced
Metagenics Omegagenics EPA DHA 300 Algae
- 300mg EPA DHA per soft gel 3 caps= 900mg 12 caps=3600mg EPA DHA
Plant Sourced Flaxseed Oil
(Flaxseed oil is primarily Alpha Linoleic Omega 3 and must be converted into EPA and DHA Omega 3 by enzymes in the body)
One Tablespoon Flax Oil can provide = 700mg EPA and DHA / 5 tablespoons= 3500mg
Barlean’s Highest Lignan Flax Oil Organic
Flora High Lignan Flax Oil Certified Organic
Azrad M, Turgeon C, and Demark-Wahnefried W. Front Oncol (2013) 3:224.
Bartsch H, Nair J, and Owen RW. Carcinogenesis (1999) 20:2209–18.
Bournoux P, et al. Br.J Cancer 2009 Dec 15:101(12):1978-85.
Tiwary S, Berzofsky J, and Terabe M. Front Immunol.18
Zanoaga O, et al. Exp Ther Med (2018) 15:1167–76.
A fundamental and groundbreaking reassessment of how we view and manage cancer
When we think of the forces driving cancer, we don’t necessarily think of evolution. But evolution and cancer are closely linked, for the historical processes that created life also created cancer. The Cheating Cell delves into this extraordinary relationship, and shows that by understanding cancer’s evolutionary origins, researchers can come up with more effective, revolutionary treatments.
Athena Aktipis goes back billions of years to explore when unicellular forms became multicellular organisms. Within these bodies of cooperating cells, cheating ones arose, overusing resources and replicating out of control, giving rise to cancer. Aktipis illustrates how evolution has paved the way for cancer’s ubiquity, and why it will exist as long as multicellular life does. Even so, she argues, this doesn’t mean we should give up on treating cancer—in fact, evolutionary approaches offer new and promising options for the disease’s prevention and treatments that aim at long-term management rather than simple eradication. Looking across species—from sponges and cacti to dogs and elephants—we are discovering new mechanisms of tumor suppression and the many ways that multicellular life-forms have evolved to keep cancer under control. By accepting that cancer is a part of our biological past, present, and future—and that we cannot win a war against evolution—treatments can become smarter, more strategic, and more humane.
Unifying the latest research from biology, ecology, medicine, and social science, The Cheating Cell challenges us to rethink cancer’s fundamental nature and our relationship to it.
Grab Your Copy Here
While there is no simple blood test for predicting who will get cancer, there is a lot of information to be gleaned from basic blood work that, taken together, reveals much about an individual’s predispositions for many forms of cancer. By monitoring selected biomarkers routinely measured in primary care, you can learn a lot about physiological patterns that promote carcinogenesis, proliferation, progression, and recurrence long before tumor markers emerge or there are radiological or pathological findings indicating cancer.
The art of assessment lies in part in recognizing the patterns. By learning how to read the multiple biochemical signals that emerge from a pro-carcinogenic “tumor microenvironment,” you can begin to practice real prevention, and give your patients the opportunity for significant improvements in both health-span and lifespan.
The tests included in this article here are ones you are routinely ordering in the integrative and functional medicine setting. While they are not to be misconstrued as diagnostic tests for cancer, they can indicate that a patient is at increased risk, and that further assessment and action is required to identify potential malignancy.
In people who’ve had cancer, these common tests are often prognostic for disease progression and recurrence.
It is vital that primary care practitioners do a better job of recognizing the early signs of recurrence among cancer survivors. According to the American Cancer Society’s 2016-2017 Survivorship Facts and Figures, the population of cancer survivors will increase to 20.3 million by January 1, 2026.
After conventional oncology treatment is finished, these patients typically return to their primary care physicians. They are highly motivated, ripe for change, and in search of clinicians who can support their efforts to restore health and prevent recurrence.
The tests described below will help you fill that role.
One of the most common biomarkers of overall health is the Complete Blood Cell panel, which can be used to monitor hematologic abnormalities caused by solid tumors, hematologic malignancies, as well as the side-effects of the therapies used to treat them.
The following findings are not definitive diagnostic signals, but taken together, they suggest that someone is at greatly increased risk:
The latter finding—a high NLR—is especially important.
Neutrophils promote cancer progression, proliferation, and metastasis by increasing vascular endothelial growth factor (VEGF), Hepatocyte growth factors, inflammatory cytokines IL-6, IL-8, matrix metalloproteinases (MMP), and elastase. Neutrophils and macrophages secrete tumor growth promoting factors and contribute to a proliferative tumor microenvironment.
Therefore a high neutrophil count is suggestive of a neoplastic process somewhere in the body.
According to a 2014 metanalysis of 57 studies, an NLR greater than 4.0 was associated with a hazard ratio for overall survival (OS) of 1.81 (95% CI = 1.67 to 1.97; P < .001), an effect observed in all disease subgroups, sites, and stages and that predicts increased risk of mortality (Templeton AJ, et al. JNCI. 2014:106(6).)
Simply put, an NLR over 4 predicts tumor progression and poor overall survival. This is a readily available and inexpensive biomarker with a lot of prognostic value.
A fasting glucose in the range of 100-126 mg/dl is suggestive of cancer risk.
Glucose may have a direct role in cancer development. Tumor cells have increased numbers of receptors for insulin, insulin-like growth factor, and GLUT4. Thus, they transport more glucose into themselves, and this promotes growth and proliferation. It is the main reason for using a low-glycemic, modified ketogenic diet in patients with cancer.
Proliferating tumor cells have up- regulated glucose transporters. Elevated serum glucose is linked to increased risk and progression of many solid cancers, including breast cancer (Haseen SD, et al. Asian Pac J Cancer Prev, 2015: 16, 675-8).
High glucose levels also result in a state of chronic inflammation, which leads to an increase of cytokines, such as interleukin 6 (IL-6), tissue necrosis factor alpha (TNF-α) and vascular endothelial growth factor (VEGF). All of these promote cancer progression, proliferation, and metastasis (Crawley DJ, et al. BMC Cancer, 14(1), 985).
Given the high prevalence of diabetes, metabolic syndrome, and insulin resistance in the US, this is an important indicator to watch.
Serum glucose is a modifiable risk factor. Diet and lifestyle changes that reduce and regulate glucose will also help to reduce risk and progression of cancer.
High Insulin & Low SHBG
Prolonged hyperinsulinemia leads to reduced hepatic production of sex hormone binding globulin (SHBG). This, in turn, increases risk of steroid hormone driven cancers. Low SHBG results in increased amounts of unbound estrogens and androgens that drive carcinogenesis in breast, endometrial, prostate lung, colorectal and pancreatic tissues.
Free unbound estrogen also exerts immunosuppressive effects in the tumor microenvironment, and has a profound impact on anti-tumor immunity and tumor-promoting inflammation that is completely independent from its direct activity on tumor cells (Svoronos N, et al. Cancer Discovery, 2017: 7(1), 72-85).
Serum albumin levels have prognostic significance in cancer, and can be used to better define baseline risk in cancer patients. It is generally useful in assessing the nutritional status, disease severity, disease progression, and prognosis.
In a multivariate analysis of 29 studies, Gupta and Lis found, “higher serum albumin levels to be associated with better survival.” (Gupta D, Lis CG. Nutrition Journal, 2010: 9(1), 69).
In the early stages of cancer, there is slight or no hypoalbuminemia. But as the disease progresses, malnutrition and inflammation suppress albumin synthesis, and albumin levels drop significantly.
Albumin levels under 3.5 g/dL are often seen in patients with sarcopenia and cachexia. Malnutrition is a predictor of reduced survival. It is also associated with deteriorating quality of life, decreased response to treatment, increased risk of chemotherapy-induced toxicity, and a reduction in cancer survival.
On the high side, albumin concentrations above 37.5 g/L are predictive of both chemotoxicity and of survival (Srdic D, et al. Supportive Care in Cancer, 2016: 24(11), 4495-4502).
It is also important to look at the Albumin-to-Globulin Ratio.
A ratio of less than 1.66 is a risk factor for cancer incidence and mortality, both short- and long term, in generally healthy screened adults. In people who’ve already developed some form of cancer, a low albumin-to-globulin ratio predicts low overall survival (Suh B, et al. Ann Ocol (2014): 25(11), 2260-2266).
Ferritin, a strong negative survival predictor, has been associated with the pathological processes of inflammation and infection. High ferritin is suggestive of inflammation, immunosuppression, tumor angiogenesis, and proliferation.
Elevated serum ferritin—indicated by levels over 200 ng/ml in men, and over 150 ng/ml in women–have been seen in people with breast cancer, pancreatic cancer, non-small cell lung cancer, hepatocellular carcinoma, leukemia, colorectal cancer and lymphoma.
High ferritin levels are significantly associated with reduced survival time and increased mortality in cancer patients (Lee S, et al. J Cancer, 2016: 7(8), 957-964)
25-OH Vitamin D Deficiency
Vitamin D has a multi-functional impact on the tumor microenvironment. Increased levels of Vitamin D are associated with reduced occurrence and reduced mortality of different types of cancer, including skin, prostate, breast, colon, ovary, kidney, and bladder.
Vitamin D is involved in a very wide range of physiological processes relevant to cancer development, including: Regulation of Gene Transcription; Growth Arrest; Apoptosis; Cellular Differentiation; DNA Repair; Antioxidant Protection; Immune Modulation; Regulation of Pro-Inflammatory Cytokines; and Control of Angiogenesis & Metastasis.
Low or suboptimal levels of 25-OH Vitamin D are associated not only with increased risk of various forms of cancer, but also with poor prognosis, and more aggressive disease (McDonnell SL, et al. PloS One, 2016: 11(4), e0152441).
This is particularly true in breast cancer. In one study, vitamin D-deficient women with breast cancer typically had more aggressive molecular phenotypes and worse prognostic indicators than those with adequate vitamin D (Williams JD, et al. Endocrinology, 2016: 157(4), 1341-1347).
The Vitamin D Council suggests repletion to 40 to 80 ng/mL, with a target of 50 ng/ml, for optimal health on multiple fronts, including colorectal cancer prevention (Bischoff-Ferrari HA, et al. Am J Clin Nutr, 2006: 84(1), 18-28).
Supplementation to reach mean serum concentrations of 72 nmol/L showed a beneficial effect against cancer development (Lappe JM, et al. Am J Clin Nutr. 2007: 85(6), 1586-1591).
When assessing patients in the context of cancer risk, the following guidelines are useful:
25 –hydroxy- Vitamin D (ng/ml)
Deficient < 50
Optimal for Cancer & CVD 70-99
Elevated Lactic Acid Dehydrogenase
Lactate dehydrogenase (LDH) is an enzyme that catalyzes the reduction of pyruvate to lactate.
Aberrant metabolism and inefficient fuel production is a characteristic of tumor cells, which are dominated by aerobic glycolysis, increased lactate production, and a higher uptake of glucose (the Warburg effect).
Elevated LDH may be a marker of these aberrant metabolic processes in cancer cells.
The normal range for LDH is thought to be 100-333 u/L, with levels greater than 245 u/L considered to be in the upper quartile of normal. Above that 245 u/L mark, it is suggestive of early carcinogenesis, tumor cell proliferation, tumor progression, and poor prognosis.
It is often highly elevated in aggressive forms of cancer and hematological malignancies including: melanoma, lymphoma, acute leukemia, seminoma germ cell, pancreatic, gastric, lung, renal cell, nasopharyngeal, esophageal, cervical, and prostate cancers (Wulaningsih W, et al. Br J Cancer. 2015:113(9). Zhang J, et al. Sci Rep. 2015:5, 9800).
CRP is elevated in patients with solid tumors, and high levels predict poor prognosis, blunted treatment response, as well as tumor recurrence.
As part of the systemic inflammatory response to a tumor, the body releases pro-inflammatory cytokines and growth factors. Interleukin-6, produced by the tumor or surrounding cells, stimulates liver production of acute-phase reaction proteins that increase C-reactive protein (CRP) and fibrinogen.
Elevated CRP correlates with disease stage and increased cancer mortality (Shrotriya S, et al. PloS One. 2015: 10(12), e0143080). Individuals with a high baseline CRP (>3 mg/L) have an 80% greater risk of early death compared with those with low CRP levels (<1 mg/L).
Patients with invasive breast cancer and CRP levels>3 mg/L at diagnosis have a 1.7 fold increased risk of death compared to those with CRP levels<1 mg/L at diagnosis (Allin KH, et al. Breast Cancer Res. 2011: 13(3), R55).
No one of the aforementioned test parameters is, in and of itself, an indicator that someone has cancer. But by looking at standard blood test results in a new way, you can start to recognize the patterns of high risk and active cancer physiology. This is crucial to early identification and early intervention.
Clinicians who are aware of the converging signs can meaningfully shift the microenvironment from one that promotes cancer to one that is not supportive of carcinogenesis, proliferation, or progression. In the same way, we can provide meaningful support for the rising tide of underserved cancer survivors and at-risk patients in need of not only a disease plan, but also a health plan.
Cancer-related cognitive impairment is attributed to both cancer as well as treatment-related changes in cytokine profiles, blood brain barrier permeability, genetic susceptibility, hormonal factors and mitochondrial dysfunction.
Both the disease itself and the treatments, can impact attention, memory and executive functions, as well, as brain structure and anatomy.
As many as 20% of all patients report continued persistent changes in cognitive function as many as 10-20 years after completing successful treatment.
1. Melatonin (10-20mg hs) - Maintains Blood Brain Barrier Integrity and Permeability
2. Astragalus (1-6g/day) - Decreases Blood Brain Barrier Permeability
3. Resveratrol (1000mg bid x 52 weeks) - Regulates Neuro-Inflammation
4. Pterobstilbene (50-100mg/d) - Attenuates Learning and Memory Impairment
5. Unique Probiotic Blend (KLAIRE Target gb-X 1 packet/day) - Targets Gut-Brain Axis
6. Curcumin (3-6g/day) - Improves Cognitive Function
7. Omega-3 Fatty Acids (1.8g/d) - Protects Neurons From Toxic Effects of Chemotherapy
8. Lion's Mane Mushroom (3-5g/d) - Enhances Cognition
By the year 2024 there will be over twenty million cancer survivors in the US alone. This rapidly growing population of survivors obliges all frontline clinicians to learn how to support patients at every stage of the cancer journey. Read more